Pfizer, Inc. Quarterly Earnings on Deck
S&P 500 (NYSE:SPY) component Pfizer, Inc. (NYSE:PFE) will unveil its latest earnings on Tuesday, August 2, 2011. Pfizer Inc. is a global pharmaceutical company which develops and manufactures prescription medications for humans and animals. Merck & Co Inc. Earnings Cheat Sheet: Profit Rises Year Over Year>>
Pfizer, Inc. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for profit of 59 cents per share, a decline of 4.8% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate was unchanged and it has not changed during the last month. For the year, analysts are projecting net income of $2.25 per share, a rise of 0.9% from last year.
Past Earnings Performance: The company has beaten estimates the last four quarters and is coming off a quarter where it topped forecasts by 2 cents, reporting profit of 60 cents per share against a mean estimate of net income of 58 cents per share.
Wall St. Revenue Expectations: On average, analysts predict $16.98 billion in revenue this quarter, a decline of 2% from the year ago quarter. Analysts are forecasting total revenue of $66.6 billion for the year, a decline of 1.8% from last year’s revenue of $67.79 billion.
Analyst Ratings: Analysts are bullish on this stock with 17 analysts rating it as a buy, none rating it as a sell and two rating it as a hold.
A year-over-year revenue decrease in the first quarter snaps a streak of three consecutive quarters of revenue increases. Revenue fell 1.5% in the first quarter and rose 6.2%in the fourth quarter of the last fiscal year, 39.2% in the third quarter of the last fiscal year and 57.7% in the second quarter of the last fiscal year.
The company has now seen net income rise in two straight quarters. In the first quarter, net income rose 9.7% from the year earlier. In the fourth quarter of the last fiscal year, the figure rose more than threefold.
Competitors to Watch: Johnson & Johnson (NYSE:JNJ), Merck & Co., Inc. (NYSE:MRK), GlaxoSmithKline plc (NYSE:GSK), Bristol Myers Squibb Co. (NYSE:BMY), Eli Lilly & Co. (NYSE:LLY), Abbott Laboratories (NYSE:ABT), Novartis AG (NYSE:NVS), Mylan Inc. (NASDAQ:MYL), Amgen, Inc. (NASDAQ:AMGN), and Sanofi-Aventis SA (NYSE:SNY).
Stock Price Performance: During May 31, 2011 to August 1, 2011, the stock price had fallen $2.44 (-11%) from $21.45 to $19.01. The stock price saw one of its best stretches over the last year between April 21, 2011 and May 2, 2011 when shares rose for seven-straight days, rising 6.2% (+$1.22) over that span. It saw one of its worst periods between July 6, 2011 and July 18, 2011 when shares fell for nine-straight days, falling 8.57% (-$1.50) over that span. Shares are up $2.14 (+12.5%) year to date.
(Source: Xignite Financials)